Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausalearly breast cancer.

Jones, S.E., Seynaeve, C., Hasenburg, A., Rea, D., Vannetzel, J.M., Paridaens, R., Markopoulos, C., Hozumi, Y., Putter, H., Hille, E., Kieback, D.G., Asmar, L., Smeets, J., Urbanski, R., Bartlett, J., van de Velde and D Rea, C., 2008.

Cancer Res 69(2 Supplement), 15. doi:10.1158/0008-5472.SABCS-15

Abstract